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Summarv To assess the role of hepatitis B e antizen (HBeAg) and its interaction with hepatitis B surface
antigen (HBsAg) on the development of hepatocellular carcinoma (HCC). this case -control study included 361
age- and sex-matched pairs of patients vwith histologically proxen HCC and healthy control subjects. HBsAg.
HBeAg and antibody to HBeAg (anti-HBe) A-ere detected by radioimmunoassay. Antibodies to hepatitis C
Virus (anti-HCV) were detected by second-generation enzyme immunoassay. The prevalences of HBeAg
(20.200). HBsAg (80.3°o) and anti-HCV (29.50o) in cases wxere higher than in controls (1.900. 20.70o and 2.7°0
respectivelyx each P<0.0001). Using patients negatixe for HBsAg. HBeAg and anti-HBe as a referent group.
univanate analysis indicated that HBsAg alone or HBsAg and HBeAg w-ere n'sk factors for HCC (P for trend
<0.0001). Calculation of incremental odds ratio indicated that there w-as additixve interaction betw-een HBsAg
and HBeAg. Multixvariate analysis indicated that HCC development w-as stronglv associated with the presence
of HBeAg (odds ratio. 8.1: 95I00 confidence interval. 2.4-27.1). HBsAg (odds ratio. 68.4: 950O confidence
interxal. 20.5-227.8) and anti-HCV (odds ratio. 59.3: 95°0 confidence interval. 13.6-258.4). In conclusion.
HBsAg. HBeAg and anti-HCV are independent nrsk factors for HCC. There is additive and independent effect
modification betwxeen HBsAg and HBeAg on the dexelopment of HCC.
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Hepatocellular carcinoma (HCC) is one of the most common
primary malignant tumours of the liver. Because sympto-
matic HCC is rarelI amenable to surgical cure and responds
poorly to chemotherapy or irradiation. there is a pressing
need to inxestigate its prevention or early diagnosis. With a
need for earl- detection. it is particularly important to
identify persons at highest risk for dexelopment of HCC. The
major risk factors of HCC include male gender. advancing
age. cirrhosis. hepatitis C virus (HCV) infection. chronic
hepatitis B surface antigen (HBsAg) camrage. alcohol abuse
and cigarette smoking (Chen et al.. 1991; Chen. 1993: Jenz
and Tsai. 1991; Tsai et al.. 1994a-J). Persistent hepatitis B
virus (HBV) infection has been clearly implicated in the
development of HCC (Chen et al.. 1991: Chen. 1993; Tsai et
al.. 1994a-f). Do all HBsAg carriers haxe an equal chance of
dexeloping HCC. and x-hat factors can be used clinically to
select patients for intensixve screening and periodic folloxw-up
examination?
Hepatitis B e antigen (HBeAg) is a protein of 159 amino
acids encoded by the preC region and the C gene of HBV
(Gupta and Shafritz. 1994: Thomas and Carman. 1994).
Although serum HBeAg has been identified for more than
three decades. its function remains to be well elucidated
(Chen. 1993. Gupta and Shafritz. 1994). The detection of
HBeAg and its corresponding antibody (anti-HBe) has
clinical and epidemiolo2ical significance. Presence of HBeAg
indicates actixve HBV replication with ongoing inflammator-
activity and progression of lixer disease. Patients w&ith HBeAg
tend to haxe more sexvere liv-er disease than those with anti-
HBe. HBeAg seroconversion. indicating a transition to viral
latency. is usually accompanied by biochemical and
histological regression of lixer disease activity (Chen. 1993:
Thomas and Carman. 1994). The reported prexalence of
HBeAg. detected by radioimmunoassay. in patients w-ith
HCC w-as between 18°o and 66°o (Chen et al.. 1991: Leung et
al.. 1994: Lin et al.. 1991: Zaman et al.. 1995). The high
prevalence of HBeAg in patients with HCC suggests that
HBeAg may be another risk factor for HCC. and HBsAg
carriers with HBeAg may be at higher risk for development
of HCC.
Although the strong association between HBV infection
and HCC has been well established. the role of HBeAg in the
development of HCC. and the interaction betxween HBsAg
and HBeAg. hax-e not been adequately explored. A case-
control study was carried out to evaluate the role of HBeAg
and its interaction w-ith HBsAg among Chinese patients with
HCC in Taiw-an.
Subjects and methods
Study population
The study population included 361 consecutix-e HCC patients
admitted to Kaohsiung Medical College Hospital from
Januar- 1991 to December 1993. All patients Nvere diagnosed
by pathology or aspiration cytology. Only new-ly diagnosed
HCC patients without previous history of cancer treatment
were enrolled. There are 303 men and 58 wxomen. w-ith a
mean age of 53+11 (mean+s.d.) years. Another 361 healthy
control pairs. A-ho entered the hospital for physical check-up.
matched by sex and age (+ 5 x-ears) to the patients (mean age.
52 + 10 years) were also enrolled. All healthy controls denied
history of previous liver disease. druz abuse. heavy drinking.
haemophilia and homosexuality. There A-as no statistical
difference in mean age and sex ratio betwxeen these two
groups. All controls hax-e normal serum transaminase levels.
All the cases and controls A-ere enrolled during the same
period. All patients and controls gave informed consent to
participate in the study. wxhich A-as approved by the
Investigation and Ethics Committee of the hospital.
Serological exaamination
All the blood specimens x-ere collected and aliquoted and
stored at -70-C until tested. All sera were tested for HBsAg.
HBeAg. anti-HBe by radioimmunoassav (Abbott Labora-
tories. North Chicago. IL. USA). Antibody to hepatitis D
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virus (anti-HDV) was detected in subjects with HBsAg by
radioimmunoassay (Abbott Laboratories). Antibodies to
hepatitis C virus (anti-HCV) were detected with Abbott
HCV EIA 2nd Generation (Abbott Laboratories). Positive
samples were retested with the same assay and another
second generation synthetic peptide-based immunoassay
(UBI HCV EIA, United Biochemical, Lake Success, NY,
USA). Only samples positive in all three tests were considered
to be anti-HCV positive.
Statistical analysis
Age-adjusted measurements of the prevalence of serum
HBeAg were calculated on the basis of standardisation by
the direct method. Unpaired Student's t-test was used to
compare the difference between means of continuous
variables. The x2 test with Yates' correction was used to
compare differences between proportions. Odds ratios with 95
per cent confidence intervals (95% CIs) were used to estimate
causal relations between risk factors and exposure. A
conditional logistic regression was used for multivariate
analysis. Adjusted odds ratios and 95% CIs were derived
from logistic regression coefficients to provide an estimate of
the statistical association between a given variable and the
disease (HCC) with the other variables held constant. The
Mantel-Haenszel extension test for trend was used to
examine the dose-response relationship for the risk
estimates of various combinations of hepatitis viral
markers. Incremental ORs were used to estimate the effect
modification between hepatitis viral markers.
To compare the population-attributable risk for anti-
HCV, HBsAg and HBeAg, the prevalence of anti-HCV
alone, HBsAg alone and both HBsAg and HBeAg in the
control group was used as the prevalence in the general
population. Population-attributable risks were calculated
from the odds ratios and the prevalence of these viral
markers in the control group. An alpha of 0.05 was used as
the indicator of statistical significance. Two-tailed P-values
and 95% CIs were given when appropriate.
Results
Prevalence ofanti-HCV, HBsAg, HBeAg and anti-HBe in
cases and controls
As shown in Table I, the prevalence of anti-HCV, HBsAg,
HBeAg in HCC patients was higher than that in healthy
controls (each P<0.0001). Although the prevalence of anti-
HBe in HBsAg-positive HCC cases was higher than that in
HBsAg-positive healthy controls (P<0.0001), the prevalence
of anti-HBe in HBsAg-negative patients was lower than that
in HBsAg-negative healthy controls (P<0.0001). A total of
304 (84.2%) patients with HCC had underlying cirrhosis.
There was no significant difference in the positive rate ofeach
viral marker regardless of coexisting cirrhosis. Among
patients with HCC, HBeAg was positive in 21.1% (64/303)
of male patients and 15.5% (9/58) of female patients. The
prevalence of HBeAg in patients younger than 40 years old
(47.6%; 20/42) was higher than that (16.6%; 53/319) in
patients older than 40 years. The difference is significant (OR,
4.6; 95% CI, 2.2-9.4). There was also an inverse trend
between increasing age and HBeAg positivity (P<0.001,
Mantel-Haenszel extension test for trend; data not shown).
There was no relation between age and HBeAg positivity
among healthy controls (data not shown). There was a
difference between age-adjusted prevalence of HBeAg
between male (21.3%) and female (13.9%) patients (P<0.01).
Riskfor HCC modified by HBV and HCV infection
Using subjects negative for HBsAg and anti-HCV as a
referent group (OR= 1.0), the risk for developing HCC was
strongly associated with the presence of HBsAg (OR=40.1)
or anti-HCV (OR=77.3) (Table II). Moreover, the risk for
developing HCC increased significantly when both markers
were considered (OR=366.4). The incremental OR and the
positive linear trend suggested an additive effect modification
between HBsAg alone and dual HBV and HCV infection
(Table II). Multivariate analysis also demonstrated that both
anti-HCV and HBsAg were independent risk factors of HCC
(Table IV).
The prevalence of HBeAg (17.2%; 10/58) in patients with
concurrent HBV and HCV infection was not significantly
different from that of patients with HBsAg alone (27.1%; 63/
232).
The independence and interaction ofHBsAg, HBeAg and anti-
HBe on the development of HCC
Using the group negative for HBsAg, HBeAg and anti-HBe
as a referent group (OR= 1.0), the risk for developing HCC
increased significantly as HBsAg became positive (Table III).
The highest OR was noted in patients positive for both
HBsAg and HBeAg, and a statistically significant positive
trend was noted based on the Mantel-Haenszel extension
test for trend (P<0.001, Table III). Moreover, calculation of
incremental odds ratios indicated that there was an additive
effect modification between HBsAg and HBeAg (Table III).
After controlling for the confounding effect of sex and age by
matching, multivariate analysis with conditional logistic
regression also indicated that both HBsAg (OR, 68.4; 95%
CI, 20.5-227.8) and HBeAg (OR, 8.1; 95% CI, 2.4-27.1) act
independently as risk factors for the development of HCC
(Table IV).
Based on a prevalence of 2.7% (10/361) for anti-HCV
alone, 18.8% (68/361) for HBsAg alone and 1.9% (7/361) for
both HBsAg and HBeAg carrier status in the control group
as well as the odds ratio associated with these three risk
factors, the estimated population-attributable risk for HCC
was 11.6% for anti-HCV alone, 34.9% for HBsAg positivity
alone, 15.8% for those positive for HBsAg and HBeAg and
15.6% for dual HBV and HCV infection in Taiwan.
Table I Prevalence of antibodies to hepatitis C virus, hepatitis B surface antigen and e antigen/antibody in patients with hepatocellular
carcinoma and healthy controls
Case Anti-HCV HBsAG+ HBeAg+ Anti-HBe+IHBsAg+ Anti-HBe+ lHBsAg- Groups no. n (%) n (%) n (%) n (%) n (%)
HCC
Cirrhotic 304 95 (31.3) 239 (78.6) 62 (20.3) 168 (55.2) 53 (17.4)
Non-cirrhotic 57 12 (21.0) 51 (89.4) 11 (19.2) 39 (68.4) 5 (8.7)
Subtotal 361 107 (29.6)a 290 (80.3)b 73 (20.2)c 207 (57.3)d 58 (16.0)
Control 361 10 (2.7)a 75 (20.7)b 7 (1.9I) 57 (15.7)d 254 (70.3)e
H(C, hepatocellular carcinoma; anti-HCV, antibodies to hepatitis C virus; HBsAg, hepatitis B surface antigen; HBeAg; hepatitis B e antigen;
anti-HBe, antibody to H)BeAg. aOdds ratio, 14.7; 95% confidence interval, 7.3-30.6 (P<0.0001). bOdds ratio. 15.6; 95% confidence interval,
10.7-22.8 (P<0.0001). COdds ratio, 12.8; 95% confidence interval, 5.6-30.9 (P<0.0001). dOdds ratio, 7.1; 95% confidence interval, 4.9- 10.3
(P<0.0001). 'Odds ratio, 0.1; 95% confidence interval, 0.1 -0.2 (P<0.0001).I and HUsAg m risk factors for HCC
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Table H Risk for hepatocellular carcnoma modified by hepatitis B surface antigen and antibodies to hepatitis C virus
HCC Control OR Incremental OR
HBsAg Anti-HCV (n=361) (n=361) (95% CI) (95% CI)
Negative Negative 22 278 .Oab
Negative Positive 49 8 77.3 (30.5-203.6)a 77.3 (30.5-203.6)
Positive Negative 232 73 40.1 (23.5-69.0) 0.5 (0.2-1.2)
Positive Positive 58 2 366.4 (79.5-791.6)ab 9.1 (2.1-32.2)c
HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; anti-HCV, antibodies to hepatitis C virus; OR, odds ratio; CI, confidence
interval. xbP<0.001 based on Mantel-Hae l extension test for trend. CP< 0.001 when the group with dual infection was compared with the
group positive for HBsAg alone (X2 test with Yates' correction).
Table H Risk for hepatocellular carcinoma related to the status of hepatitis B surface antigen and e antigen/antibody
HCC Control OR Incremental OR
HBsAg HBeAg Anti-HBe (n =361) (n =361) (95% CI) (95% CI)
13 32 1.0
-- + 58 254 0.6 (0.3-1.2) 0.6 (0.3- 1.2)
+ 15 11 3.4 (1.1-10.5)a 6.0 (2.4-14.8)
+ + 202 57 8.7 (4.1-18.9r 2.6 (1.1-6.4)
+ + - or + 73b 7b 25.7 (8.5-81.2)- 2.9 (1.2-7.4)
P<0.001 based on Mantel-Haenszel extension test for trend. HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HBeAg,
hepatitis B e antigen; anti-HBe, antibody to HBeAg; OR, odds ratio; CI, confidence interval; +, positive; -, negative. aP<0.00l when other
categories werecompared with the groupnegative forHBsAg, HBeAg and anti-HBe. bFive HCCpatients and onehealthycontrol were anti-HBe-
positive.
Table IV Risk for hepatocellular carcinoma evaluated by conditional logistic regression analysis of the comparison
between patients with hepatocellular carcinoma and healthy controls
Regression Standard Odds ratio (95%
Variables coeffcient error P-value confuience interval)
Anti-HCV 4.08 0.75 0.0001 59.3 (13.6-258.4)
HBsAg 4.22 0.61 0.0001 68.4 (20.5-227.8)
HBeAg 2.10 0.61 0.0001 8.1 (2.4-27.1)
Anti-HCV, antibodies to hepatitis C virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen.
Disas
Taiwan is an endemic area of hepatotropic viral hepatitis
(Chen, 1993; Chen et al., 1992; Tsai et al., 1990a-c, 1991,
1993, 1994a-h, 1995a-d, 1996). Chronic hepatitis is common.
Liver cirrhosis and HCC are two of the ten leading causes of
death in this country since the 1980s. The recently reported
HBsAg carrier rate in the adult general population is around
15-20% (Chen et al., 1992; Chen 1993) and the prevalence
of serum-anti-HDV is relatively low (2.2%) (Chen et al.,
1992). The prevalence of HBsAg (20.7%) and anti-HCV
(2.7%) in our healthy controls was similar to that in
community controls from the same area (Tsai et al.,
1994b,e). So we conclude that our healthy controls represent
the general Taiwanese population. In this study, none of the
healthy controls and only four (1.3%) out of 290 HBsAg-
positive patients are positive for anti-HDV. Our result
confirmed the previous observation that HDV infection was
infrequent in HCC in Taiwan (Chen et al., 1984). Chinese
men who are carriers of HBsAg and/or anti-HCV have a very
high risk ofdeveloping HCC that increases in the presence of
cirrhosis and with advancing age (Chen, 1993; Chen et al.,
1991; Lin et al., 1991; Jeng and Tsai, 1991; Tsai et al., 1994a-
c,ef, 1995d). In this study, the confounding effect of age and
sex was adjusted by matching the controls and by multi-
variate analysis (Table IV). Our results agreed with the well-
established strong association between HBV and HCV
infection and the development of HCC (Lin et al., 1991;
Chen, 1993; Gupta and Shafritz, 1994; Tsai et a!., 1994a-J).
Chronic HBV infection can induce HCC by a variety of
virus-specific mechanisms and virus-non-specific general
mutagenesis mechanisms (Schirmacher et al., 1993; Gupta
and Shafritz, 1994). HBV may act as a complete carcinogen
by 'initiating' the carcinogenic process through HBV-DNA
integration. In the evoluation of chronic liver disease,
episodic necroinflammation has been considered important
not only in promoting malignant transformation (Kew and
Popper, 1984; Popper et al., 1988) but also as an
endogeneous cocarcinogen (Popper et al., 1988). Chronic
hepatitis and cirrhosis lead to immune-mediated permanent
cell death and thus continuous regeneration that constitutes a
general mutagenic mechanism (Schirmacher et al., 1993). In
this study, 84% ofpatients had underlying cirrhosis, whereas
16% of patients had concurrent HCV and HBV infection
(Table II). Liver disease tends to be more severe in patients
with concurrent HBV and HCV infection than in patients
with single HBV infection (Tsai et al., 1993; 1995b,c, 1996).
Such chronic liver disease may also cause episodic
necroinflammation. Thus, in hepatotropic virus-associated
HCC, such a virus-non-specific mechanism should be taken
into consideration. This may explain the additive effect of
both viruses as risk factors for HCC. However, this
observation warranted further evaluation, as the number of
subjects with both markers in the control group was small.
As shown in Table I, the risk for HCC in patients with
past HBV infection (HBsAg-negative/anti-HBe-positive) is
most likely different from patients with ongoing HBV
infection (HBsAg/anti-HBe-positive). In this study, 81.7%
(58/71) of HCC patients were HBsAg-negative/anti-HBe-
positive and positive for antibody to HBsAg (anti-HBs)
(Table I). Co-infection of these patients with other
hepatotropic viruses might cause episodic necroinflammation
and act as an important cofactor (Gupta and Shafritz, 1994;
Tsai et al., 1994a-h 1996). Although the possibility thatIUsAgI9 m ad HBsAg as rhk factoirs for HCC
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transient HBV infection, as occurred in our anti-HBs-positive
patients, might cause hepatocarcinogenesis through a 'hit and
run' mechanism (Galloway and McDougall, 1983), transient
infection alone cannot explain accompanying chronic liver
disease. Therefore, prior HBV infection could still be
pathogenetically linked to the development of HCC
(Schirmacher et al., 1993; Gupta and Shafritz, 1994).
In this study, by using a more formal epidemiological
approach, we are trying to assess whether HBeAg is an
independent risk factor for HCC. Regardless of concurrent
HBV and HCV infection or HBV infection alone, our results
indicated that the HBeAg-positive rate is significantly higher
among HCC patients compared with controls (Table I).
These data suggest an aetiological relation of HBeAg to
HCC. Both univariate and multivariate analyses indicated
that HBeAg and HBsAg acted as additive and independent
risk factors for the development of HCC (Table HI, IV).
These results indicated that HBeAg might increase HCC risk
associated with HBsAg. Their existence appeared to operate
a strong oncogenic effect on liver cells. However, the
estimated population-attributable risk indicated that HBsAg
alone is still the main risk factor of HCC, and HBeAg might
only be a cofactor of HBsAg. It is not clear why the presence
of HBsAg and HBeAg expedite hepatocarcinogenesis. The
relative importance of HBsAg and HBeAg as initiators or
cofactors in the chain of events leading to HCC is still
disputed. The presence of HBeAg in serum often correlated
with viral replication and continuous liver inflammation
(Chen, 1993; Gupta and Shafritz, 1994). It is unknown at
present whether HBeAg increase HCC risk through causing
chronic necroinflammation in the liver.
Although HBeAg may represent active HBV replication,
HBV-DNA may be a better marker of ongoing viral
replication (Chen 1993, Gupta and Shafritz, 1994). Anti-
HBe/HBV-DNA-positive patients, with or without precore
mutant, may have active liver disease and progress to HCC
(Raimondo et al., 1991; Chen, 1993; Thomas and Carman,
1994). This may explain, at least in part, the higher odds
ratio in anti-HBe/HBsAg-positive patients with HCC (Table
I). As we have not detected HBV-DNA in this study, this
hypothesis awaits further study. Moreover, co-infection with
other hepatotropic viruses in anti-HBe/HBsAg-positive
patients may influence the magnitude of the risk for HCC.
In this study we address the evidence at a population level
for the additive and independent effect of HBeAg, although
of a lesser magnitude than HBsAg, on the development of
HCC. As this is a case-control study, the limitation of a
retrospective study for examining aetiology should be kept in
mind even though it can be argued that the role of HBV in
the aetiology of HCC is well enough known that the
chronology of exposure (HBsAg and HBeAg) and outcome
(HCC) is unlikely to be seriously in doubt. In conclusion,
there is an additive and independent effect modification
between HBeAg and HBsAg on the development of HCC.
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